PRLD Prelude Therapeutics Incorporated

XNAS 3.70 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

PRLD $3.70 —
Key stats
$3.70
52-Week Range
$1.17 – $6.83
YTD
+35.53%
Straddle Price
$1.27
P/C Vol Ratio
50.00
Market Cap
$0.3B
Open
$3.63
Day Range
$3.40 – $3.74
Volume
236,859
Prev Close
$3.63
Fair Value
MODEL: NEUTRAL

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.15
Cost of Equity (CAPM)11.27% (VRP-adj)
WACC11.44%
Volatility Risk Premium+152.0pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-45.2%
Book / Price42.9% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-148.3%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$4.61 (Market Anchor value)
SMA 20 / Bollinger Mid$3.66
Bollinger Width / SMA20637.2% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
15%
20-Day Fair Value
≈ by Nov 25, 2026
$3.69
α -0.2% rank 35%
conviction
11%
40-Day Fair Value
≈ by Dec 24, 2026
$3.72
α +0.4% rank 35%
conviction
14%
60-Day Fair Value
≈ by Jan 22, 2027
$3.69
α -0.4% rank 35%
conviction
15%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.5× · 3 peers
Peer EV/EBITDA n/a 0% median 19.2× · 3 peers
Peer P/B $5.58 50% median 3.5× · 3 peers
Peer P/S $1.03 50% median 3.9× · 3 peers
Market Anchor (SMA50) $4.61 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.3B
Employees
79
List Date
2020-09-25
CIK
0001678660
Next Earnings
2026-11-11 (Pre-Market)
EPS Forecast
($0.14) (2 est.)
Headquarters
Wilmington, DE
Homepage
https://www.preludetx.com

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-3.72%-24.89%27.09%-19.41%-12.00%-32.23%-10.86%
Feb-10.29%-13.69%-14.11%31.50%-31.62%35.96%-0.37%
Mar-35.99%-18.54%-3.88%3.27%12.28%26.20%-2.78%
Apr0.46%-36.69%-2.12%-19.62%24.59%51.59%3.04%
May-14.13%-13.58%-9.42%3.22%-3.54%-16.60%-9.01%
Jun-13.22%23.99%-19.06%3.25%-10.77%39.53%3.95%
Jul12.03%-5.66%-13.50%68.97%-2.51%-6.69%8.77%
Aug12.48%42.57%1.08%-7.96%46.08%27.56%20.30%
Sep-15.72%-13.82%-15.57%-59.41%27.43%-28.78%-17.64%
Oct-44.61%-1.76%-38.88%-40.89%5.30%-2.37%*-20.54%
Nov-22.00%0.30%77.96%-15.32%-57.79%---3.37%
Dec-9.45%-8.62%32.40%21.43%87.10%--24.57%
Total-82.80%-62.61%-19.96%-64.03%9.34%69.76%-25.05%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $3.66
SMA 50: $4.61
SMA 200: $3.98
Current: $3.70
EMA 12: $3.62
EMA 26: $3.86
MACD: -0.2436 | Signal: 0.0657
BEARISH
ADX (14): 35.67
TREND
+DI: 14.08
−DI: 21.91

Momentum Oscillators

RSI (14): 44.15
NEUTRAL
Stoch %K: 54.51
Stoch %D: 51.90
Williams %R: -38.82

Volume & Volatility

BB Upper: $4.08
BB Lower: $3.23
NEUTRAL
OBV: 19,666,634
Vol SMA 20: 499,208
Vol ROC: 20.51%
ATR: $0.29
True Range: $0.34
HV 20: 54.8%
HV 30: 65.4%
HV 60: 74.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

SYMBOL: PRLD CURRENT PRICE: $4.27

Executive Summary Overall Assessment: NEUTRAL (Confidence Level: 7/10) Key Drivers and Primary Risks: + Strong technical momentum, with MACD and RSI in bullish territories. + Recent positive news headlines on cancer research and clinical trial data. + High volatility, with beta exceeding market (2.09 vs SPY). + Options market pricing a potential move of $1.25 by expiration.

Technical Analysis Trend Direction: SHORT-TERM (1-4 weeks): UPTREND; MEDIUM-TERM (1-3 months): UPTREND Support/Resistance Levels: + Lower Bollinger Band: $4.07 + Middle Bollinger Band: $4.61 + Upper Bollinger Band: $5.15 Momentum Signals: + RSI (14): 46.70 (NEUTRAL) + MACD: Bullish crossover above signal line + Bollinger Bands: Neutral, with price touching the middle band

News & Sentiment Analysis Recent Headlines Summary: Positive news on cancer research and clinical trial data. Sentiment Assessment: POSITIVE Catalyst Identification: Upcoming healthcare conferences, FDA approvals, or product launches.

Risk & Volatility Assessment Beta Interpretation: HIGH RISK (2.09 vs SPY) Volatility Regime: CURRENT VOLATILITY: HIGH (1.99); HISTORICAL VOLATILITY: 98.2% (HV20), 127.9% (HV30), and 118.5% (HV60)

Market Context & Positioning Sector Performance: Relative strength vs sector/market Institutional Activity: Institutional interest signals through volume patterns. Correlation Analysis: PRLD moves more than the market (0.13 R-squared interpretation).

Key Levels & Action Items Critical Price Levels: Support: $4.07; Resistance: $5.15 Breakout/Breakdown Levels: Short-term support at $4.27, potential breakout above $5.15. Time-Sensitive Catalysts: Upcoming healthcare conferences, FDA approvals, or product launches. Risk Management: Stop-loss levels and position sizing considerations based on volatility and risk appetite.

Conclusion: PRLD's technical momentum is strong, with MACD and RSI in bullish territories. Recent positive news headlines support this trend. However, the stock's high volatility and beta exceeding market highlight potential risks. Options market pricing a potential move of $1.25 by expiration suggests opportunities for traders to take advantage of price movements. Overall, I maintain a NEUTRAL outlook with caution due to the company's high-risk profile.

Note: This analysis focuses on risk/reward assessment only and does not provide buy/sell recommendations.

Generated
News
All PRLD news →
Earnings History
13 of 13 under expected move
Avg Expected Move
247.25%
Avg Actual Move
6.31%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2023-05-08 Pre-Market 22.73% 2.15% 0.09x Within
2023-08-03 Pre-Market 72.80% 3.73% 0.05x Within
2023-11-01 Pre-Market 134.92% 10.06% 0.07x Within
2024-05-07 Pre-Market 39.69% 3.39% 0.09x Within
2024-08-12 Pre-Market 35.29% 6.86% 0.19x Within
2024-11-06 Pre-Market 144.26% 2.33% 0.02x Within
2025-03-10 Pre-Market 835.60% 8.97% 0.01x Within
2025-05-06 After-Close 813.44% 3.98% 0.00x Within
2025-08-14 Pre-Market 771.78% 4.19% 0.01x Within
2025-11-12 Pre-Market 272.22% 8.89% 0.03x Within
2026-03-10 Pre-Market 33.17% 16.50% 0.50x Within
2026-05-12 Pre-Market 16.67% 3.33% 0.20x Within
2026-08-11 After-Close 21.62% 7.71% 0.36x Within

Earnings calendar: this week’s reports with expected vs actual moves →

PRLD Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $1.27
7-DTE Move: $1.27
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 1
Put Volume: 50
P/C Volume: 50.0
BEARISH
Call OI: 28
Put OI: 100
P/C OI: 3.571
Total OI: 128

ATM Options Pricing

ATM Call: $1.20
ATM Put: $0.07
Call %: 32.4%
Put %: 2.0%

Chain Summary

Chain Volume: 178
Chain OI: 1,765
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 54th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
54%
vs own history
GEX tilt
+0.91
OI-weighted, today
Vanna tilt
+0.90
δ-sensitivity to IV
Charm tilt
-0.92
δ-decay vs time
Vanna tilt +0.90: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.92: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 4 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 146.0% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.27Oct 26
Beta Analysis

Risk Metrics

Beta: 1.9002
Alpha: 203.53%
Correlation: 0.1240
R-Squared: 1.5%
Stock Volatility: 195.4%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own PRLD
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$4.5M
0.00%
#2115 of 3716+120.8%13F
Renaissance Technologies Hedge fund
Jim Simons
$1.5M
0.00%
#2123 of 3138+2.2%13F
Citadel Hedge fund
Ken Griffin
$120K
0.00%
#5705 of 6285-81.9%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

PRLD Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 84,188,282 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

79 filers51,015,324 shares$268.44M value60.60% of float
# Filer Shares Value % of Total % of Float Period
1 ORBIMED ADVISORS LLC 13,724,571 $73.15M 27.25% 16.30% 2026-06-30
2 BAKER BROS. ADVISORS LP 10,123,824 $53.96M 20.10% 12.03% 2026-06-30
3 RA CAPITAL MANAGEMENT, L.P. 6,475,882 $34.52M 12.86% 7.69% 2026-06-30
4 Soleus Capital Management, L.P. 3,378,378 $18.01M 6.71% 4.01% 2026-06-30
5 Kynam Capital Management, LP 2,415,087 $12.87M 4.80% 2.87% 2026-06-30
6 Vanguard Capital Management LLC 2,009,445 $10.71M 3.99% 2.39% 2026-06-30
7 BlackRock, Inc. Custodian 1,797,501 $9.58M 3.57% 2.14% 2026-06-30
8 SPHERA FUNDS MANAGEMENT LTD. 1,019,832 $5.44M 2.02% 1.21% 2026-06-30
9 Two Sigma Investments, LP Custodian 993,369 $5.29M 1.97% 1.18% 2026-06-30
10 ADAR1 Capital Management, LLC 900,900 $4.80M 1.79% 1.07% 2026-06-30
11 Millennium Management LLC Custodian 844,993 $4.50M 1.68% 1.00% 2026-06-30
12 Geode Capital Management, LLC Custodian 841,862 $4.49M 1.67% 1.00% 2026-06-30
13 Vanguard Group Inc Custodian 1,413,986 $4.10M 1.53% 1.68% 2025-12-31
14 ADAGE CAPITAL PARTNERS GP, L.L.C. 766,095 $4.08M 1.52% 0.91% 2026-06-30
15 ACADIAN ASSET MANAGEMENT LLC 611,359 $3.25M 1.21% 0.73% 2026-06-30
16 Morgan Stanley Custodian 503,860 $2.69M 1.00% 0.60% 2026-06-30
17 State Street Corp 428,787 $2.29M 0.85% 0.51% 2026-06-30
18 UBS Group AG Custodian 318,797 $1.70M 0.63% 0.38% 2026-06-30
19 Vanguard Fiduciary Trust Co 284,886 $1.52M 0.57% 0.34% 2026-06-30
20 RENAISSANCE TECHNOLOGIES LLC 281,200 $1.50M 0.56% 0.33% 2026-06-30
21 Northern Trust Corp Custodian 240,599 $1.28M 0.48% 0.29% 2026-06-30
22 Vanguard Portfolio Management LLC 193,920 $1.03M 0.39% 0.23% 2026-06-30
23 Marshall Wace, LLP Custodian 190,692 $1.02M 0.38% 0.23% 2026-06-30
24 Connor, Clark & Lunn Investment Management Ltd. 125,606 $669.48K 0.25% 0.15% 2026-06-30
25 Goldman Sachs Group Inc Custodian 120,834 $644.04K 0.24% 0.14% 2026-06-30
3 filers$1.02M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $591.63K 58.05% 2026-06-30
2 Jane Street Group, LLC Custodian $341.65K 33.53% 2026-06-30
3 Citadel Advisors LLC Custodian $85.81K 8.42% 2026-06-30
3 filers$613.48K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $339.52K 55.34% 2026-06-30
2 Citadel Advisors LLC Custodian $166.83K 27.19% 2026-06-30
3 Jane Street Group, LLC Custodian $107.13K 17.46% 2026-06-30

PRLD Insider Trading (Form 4)

Latest: 2026-06-10
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-10 Paul A Friedman Director Grant (A) +38,000 opt — EDGAR
2026-06-10 David P Bonita Director Grant (A) +38,000 opt — EDGAR
2026-06-10 Victor Sandor Director Grant (A) +38,000 opt — EDGAR
2026-06-10 Katina Dorton Director Grant (A) +38,000 opt — EDGAR
2026-06-10 Martin Babler Director Grant (A) +38,000 opt — EDGAR
2026-06-10 Julian Baker Director Grant (A) +456,000 opt — EDGAR
2026-05-04 Charles Q Morris Chief Medical Officer Grant (A) +450,000 opt — EDGAR
2026-04-28 Rajeev M. Shah 10%+ Owner Other (J) −5,628,000 — EDGAR
2026-04-23 David P Bonita Director Buy (P) +2,815,315 $4.44 $12.50M EDGAR
2026-04-23 ORBIMED CAPITAL LLC Director Buy (P) +11,261,260 $4.44 $50.00M EDGAR
2026-04-22 BAKER BROS. ADVISORS LP Director Buy (P) +13,513,512 RSU — EDGAR
2026-02-05 Peggy Scherle Chief Scientific Officer Grant (A) +230,000 opt — EDGAR
2026-02-05 Krishna Vaddi CEO Grant (A) +837,000 opt — EDGAR
2026-02-05 Bryant David Lim CLO, CFO, Corp Sec. Grant (A) +275,000 opt — EDGAR
2026-02-05 Andrew Combs Chief Chemistry Officer Grant (A) +230,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

PRLD Insider Holdings

10 insiders · @ $3.70
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Rajeev M. Shah 10%+ Owner 6,475,882 $23.96M $0 1 2026-04-28
2 Krishna Vaddi CEO 2,422,951 $8.96M $873.7K 18 2026-02-05
3 ORBIMED CAPITAL LLC Director 1,126,126 $4.17M $65.00M 3 2026-04-23
4 David P Bonita Director 1,126,126 $4.17M $41.00M 10 2026-06-10
5 Paul A Friedman Director 500,098 $1.85M $0 7 2026-06-10
6 Andrew Combs Chief Chemistry Officer 480,123 $1.78M $268.7K 11 2026-02-05
7 Peggy Scherle Chief Scientific Officer 176,234 $652.1K -$2.26M 12 2026-02-05
8 Jane Huang President, CMO 86,917 $321.6K -$81.3K 15 2025-10-07
9 Bryant David Lim CLO, CFO, Corp Sec. 27,400 $101.4K $35.6K 7 2026-02-05
10 Mardi Dier Director 10,000 $37.0K $190.0K 7 2025-06-13
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

PRLD Board & Officers

As of SEC filings through Jun 10, 2026

Directors 17

Officers 6

10% owners 11

Changes in the last 10 years (60)
Apr 28, 2026Rajeev M. Shah reported in an SEC filing no longer being a 10% owner
Apr 28, 2026Ra Capital Management, L.p. reported in an SEC filing no longer being a 10% owner
Apr 28, 2026RA Capital Healthcare Fund LP reported in an SEC filing no longer being a 10% owner
Apr 28, 2026Peter Kolchinsky reported in an SEC filing no longer being a 10% owner
Apr 23, 2026OrbiMed Genesis GP LLC first on file as a director
Apr 23, 2026OrbiMed Genesis GP LLC first on file as a 10% owner
Apr 21, 2026Rajeev M. Shah became a 10% owner
Apr 21, 2026Ra Capital Management, L.p. became a 10% owner
Apr 21, 2026RA Capital Healthcare Fund LP became a 10% owner
Apr 21, 2026Peter Kolchinsky became a 10% owner
Apr 15, 2026Charles Q Morris became Chief Medical Officer
Mar 5, 2026Sean P. Brusky became Chief Business Officer
Nov 4, 2025The company announced the departure of Jane Huang as President, CMO in an SEC filing
Oct 17, 2025Katina Dorton became a director
Oct 15, 2025The company announced the departure of Mardi Dier from the board in an SEC filing
Jun 12, 2025Paul C Scherer became a director
Feb 5, 2025Bryant David Lim listed as CLO, CFO, Corp Sec. (previously CLO, Interim CFO, Corp Sec.) in SEC filings
May 16, 2024Bryant David Lim listed as CLO, Interim CFO, Corp Sec. (previously Chief Legal Officer, Corp Sec.) in SEC filings
Apr 8, 2024The company announced the departure of Laurent Chardonnet as Chief Financial Officer in an SEC filing
Mar 4, 2024Andrew Combs listed as Chief Chemistry Officer (previously EVP, Head of Chemistry) in SEC filings
Not reported recently (3)
  • David J Mauro · Last reported as Chief Medical Officer in an SEC filing dated Oct 6, 2021
  • Christopher Pierce · Last reported as EVP and Chief of Business Oper in an SEC filing dated Sep 7, 2021
  • Kelvin Neu · Last reported as a director in an SEC filing dated Sep 24, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
21 ETFs hold PRLD
21 shown · $12.21M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $5.9M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.00% $2.5M $74.6B 2026-10-23
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $1.4M — 2026-09-30
4 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.01% $953,721 $13.7B 2026-10-23
5 VTWO Vanguard Russell 2000 ETF Vanguard 0.00% $628,224 — 2026-09-30
6 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.03% $308,996 $1.2B 2026-10-23
7 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.01% $117,871 — 2026-09-30
8 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.00% $104,464 $3.2B 2026-10-23
9 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $72,222 — 2026-10-23
10 OMFS Invesco Russell 2000 Dynamic Multifactor ETF Invesco 0.03% $71,086 — 2026-10-24
11 DFMC Dimensional US Micro Cap ETF Dimensional 0.00% $65,173 — 2026-10-23
12 RSSL Global X Russell 2000 ETF Global X 0.00% $50,150 — 2026-10-26
13 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $22,978 — 2026-10-23
14 DFSU Dimensional US Sustainability Core 1 ETF Dimensional 0.00% $12,062 $2.4B 2026-10-23
15 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $6,721 — 2026-09-30
16 ITWO ProShares Russell 2000 High Income ETF ProShares 0.00% $5,872 — 2026-10-26
17 URTY ProShares UltraPro Russell2000 ProShares 0.00% $4,507 — 2026-10-26
18 FSEG Fidelity Enhanced Small Cap Growth ETF Fidelity 0.04% $3,191 $7.6M 2026-10-23
19 UWM ProShares Ultra Russell2000 ProShares 0.00% $3,164 — 2026-10-26
20 HDG ProShares Hedge Replication ETF ProShares 0.00% $126 — 2026-10-26
21 RB ProShares Russell 2000 Dynamic Buffer ETF ProShares 0.00% $37 — 2026-10-26
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.74
TTM Revenue
$22.42M
TTM Net Income
$-60.49M
TTM Op. Cash Flow
$-33.26M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$5.70M$-13.92M$-0.14$-15.57M
Q1 '262026-03-31$4.58M$-10.38M$-0.13$-21.68M
Q4 '252025-12-31$5.64M$-16.46M$-0.20$23.12M
Q3 '252025-09-30$6.50M$-19.73M$-0.26$-19.11M
Q2 '252025-06-30—$-31.23M$-0.41$-26.07M
Q1 '252025-03-31—$-32.09M$-0.42$-34.23M
Q4 '242024-12-31$4.00M$-28.73M$-0.38$-20.74M
Q3 '242024-09-30$3.00M$-32.27M$-0.43$-27.30M
Q2 '242024-06-30—$-34.74M$-0.46$-23.06M
Q1 '242024-03-31—$-31.43M$-0.42$-31.79M
Q4 '232023-12-31—$-33.08M$-0.47$-23.58M
Q3 '232023-09-30—$-30.61M$-0.45$-25.68M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.33
P/S
13.89
EV/EBITDA
—
EV/Sales
12.72
ROE
-45.2%
ROA
-31.9%
Div Yield
0.00%
FCF Yield
-10.68%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$311.50M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
4.58M
SI % of Float
11.82%
Days to Cover
7.91
Short Vol Ratio
66.8%
Free Float
38.72M
Float %
48.5%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14